DOI: 10.1007/s00259-018-4183-0Pages: 1-9

Myocardial MIBG scintigraphy in genetic Parkinson’s disease as a model for Lewy body disorders

1. Biocruces-Bizkaia Health Research Institute, Neurodegenerative Diseases Group

2. Cruces University Hospital, Neurology Department

3. Cruces University Hospital, Nuclear Medicine Department

4. University of the Basque Country (UPV/EHU), Department of Neurosciences

5. Biocruces-Bizkaia Health Research Institute, Computational Neuroimaging Group

6. Ikerbasque: The Basque Foundation for Science

7. University of the Basque Country (UPV/EHU), Department of Cell Biology and Histology

Correspondence to:
Iñigo Gabilondo
Tel: +34 946006000
Email: igabilon@gmail.com

Close

Abstract

Purpose

To identify myocardial sympathetic denervation patterns suggestive of Lewy body (LB) pathology in patients with genetic and idiopathic parkinsonisms by 123I-metaiodobenzylguanidine (MIBG) scintigraphy.

Methods

We retrospectively analysed myocardial MIBG images acquired with a dual-head gamma camera and low-energy high-resolution collimator (LEHR) in 194 patients with suspected synucleinopathy or atypical parkinsonism, including 34 with genetic Parkinson’s disease (PD; 4 PARK1, 8 PARK2 and 22 PARK8), 85 with idiopathic PD (iPD), 6 with idiopathic REM sleep behaviour disorder (iRBD), 17 with dementia with LB (DLB), 40 with multiple system atrophy (MSA) and 12 with progressive supranuclear palsy (PSP), and in 45 healthy controls. We calculated heart-to-mediastinum MIBG uptake ratios (HMR) at 15 min and 4 h (HMR4H) for the LEHR and standardized medium-energy collimators, to obtain classification accuracies and optimal cut-off values for HMR using supervised classification and ROC analyses.

Results

While patients with LB disorders had markedly lower HMR4HLEHR than controls (controls 1.86 ± 0.26, iPD 1.38 ± 0.29, iRBD 1.23 ± 0.09, PARK1 1.20 ± 0.09, DLB 1.17 ± 0.11; p < 0.05), for the remaining patient categories differences were smaller (PARK8 1.51 ± 0.32; p < 0.05) or not significant (MSA 1.82 ± 0.37, PSP 1.59 ± 0.23, PARK2 1.51 ± 0.30; p > 0.05). The diagnostic accuracy of HMR4HLEHR was highest in patients with LB disorders (PARK1, iPD, DLB, iRBD; 89% to 97%) and lowest in those with PARK2, PARK8, PSP and MSA (65% to 76%), with an optimal HMR4HLEHR cut-off value of 1.72 for discriminating most patients with LB disorders including iPD and 1.40 for discriminating those with aggressive LB spectrum phenotypes (DLB, PARK1 and iRBD).

Conclusion

Our study including patients with a wide spectrum of genetic and idiopathic parkinsonisms with different degrees of LB pathology further supports myocardial MIBG scintigraphy as an accurate tool for discriminating patients with LB spectrum disorders.

To access the full text, please Sign in

If you have institutional access, please click here

  • Accepted: Sep 17, 2018
  • Online: Oct 15, 2018

Article Tools

eanm
EJNMMI Ad